Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
J Edelmann; E Tausch; D A Landau; S Robrecht; J Bahlo; K Fischer; A M Fink; J Bloehdorn; K Holzmann; S Böttcher; L Werner; M Kneba; J G Gribben; D S Neuberg; C J Wu; M Hallek; H Döhner; S Stilgenbauer
Author Information: Internal Medicine III, Ulm University, Ulm, Germany;
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.